Overview

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have relapsed or refractory acute lymphocytic leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Hannover Medical School
Treatments:
Asparaginase
Cytarabine
Daunorubicin
Dexamethasone
Etoposide
Idarubicin
Ifosfamide
Leucovorin
Levoleucovorin
Methotrexate
Prednisolone
Vindesine